FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

LAURUSLABS Consensus Forecast

No. of reports in last year
4
No. of analysts
3
Average Consensus Forecast
433.75
Consensus Potential
-56.15%

LAURUSLABS Price Target Potential

BrokerageTargetPotential
ICICIdirect.com550-18.84%
Sharekhan450-45.24%
Motilal Oswal410-59.41%

LAURUSLABS Targets in FrontPage Forums

13 Users have submitted 13 trade ideas of Rs. 488,108.7 for LAURUSLABS
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

LAURUSLABS Ratings

Long term LAURUSLABS rating by FrontPage users
5/5 (3 Ratings)

4 LAURUSLABS share price target reports by brokerages below. See what is analyst's view on LAURUSLABS share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. LAURUSLABS Forum
  3. LAURUSLABS Price Target

LAURUSLABS Share Price Target

LAURUSLABS Share Price Target - Broker Reports - 2021

30-Apr-21
Price @ Call: 453.1
Target: 550
BUY
10-Mar-21
Price @ Call: 364.8
Target: 450
BUY

LAURUSLABS Share Price Target - Broker Reports - 2020

26-Nov-20
Price @ Call: 293.32
Target: 410
BUY
29-Sep-20
Price @ Call: 294.4
Target: 325
HOLD

LAURUSLABS Share Price Target - Broker Reports - 2019

5-Aug-19
Price @ Call: 319.09
Target: 471
BUY
We maintain a BUY on Laurus despite poor operational performance in 1QFY20. After adjusting for lack of scale up in ARV APIs and buoyancy in formulation segment, we have cut our FY20/21E numbers by 5-8% to arrive at a TP of Rs 470/sh (18x FY21E EPS).Laurus is sitting on ~40% underutilized gross block (~Rs 0.9bn) spread across formulations, CRAMS and API segments. With a sharp jump witnessed in formulations and higher visibility of CRAMS orders for FY20, we are confident that the operating/ financial leverage story will unfold from FY20. Assuming formulations revenues/ EBITDA at US$ 85/ 25mn in FY21E, earnings are likely to grow 2.5x over FY19-21E. With all four ARV formulation approvals (TLD, TLE 400, TLE 600, TEE) in place by 1HFY21, addressing >US$ 1.2bn opportunity, the estimates could be breached easily. Maintain BUY.
... Read more
17-Jul-19
Price @ Call: 347.45
Target: 515
BUY
Laurus has a high visibility on the offtake in formulations to continue over FY20 with orders in hand for third-party contracts in EU, 3 approvals in the US, and supplies to GF. It expects approvals for TLE/TEE in CY19. With 8-10 yearly ANDA filings, Laurus is likely to achieve a similar no. of approvals, which will boost US revenues. On the margins front, ramp up in formulations will drive gross margin and oplev. We expect a 14/38/63% revenue/EBITDA/PAT CAGR over FY19-21E (low base). Maintain BUY with a TP of Rs 515 (18x FY21E EPS).
... Read more
1-Jul-19
Price @ Call: 346.52
Target: 430
BUY
We expect strong volume growth in oncology and other API segments, given the ongoing supply issues in the API industry. We also expect continued growth in other segments, particularly synthesis, which should grow at 25% CAGR from FY19-21. We continue to see value in the stock, with the recent ARV formulation supplies to Global Fund and strong ramp-up in synthesis providing visibility on growth, given pressures in EFV API. BUY; fair value Rs.430, based on ~15X FY21E EPS.
... Read more
6-May-19
Price @ Call: 397.85
Target: 470
BUY
We maintain our earnings estimates for FY20/21E. We remain positive on LAURUS as we expect 55% earnings CAGR over FY19-21, backed by incremental formulation business, addition of new molecules in the API category, and strong momentum in the synthesis segment. We continue to value LAURUS at 18x 12M forward earnings to arrive at price target of INR470 (unchanged). Re-iterate BUY.
... Read more
26-Apr-19
Price @ Call: 388.2
Target: 417
BUY
India imports around 60% of Active Pharmaceutical Ingredients - raw materials required to make finished drugs from China on volume basis. This is despite the cost of manufacturing of APIs being similar in India as well as China. It is estimated that around US$ 40bn worth of drugs in the US and US$ 25bn worth of drugs in Europe will be going off patent (series of patent expirations of important prescription drugs) in the coming years. Thus, we feel that the factors augur well for players like Hikal, Laurus labs, Granules, Dishman Carbogen (DCAL) etc. We have recommended buy on Hikal and Laurus labs with TP of Rs 218 and Rs 478 over the next 4 quarters, respectively.
... Read more
11-Apr-19
Price @ Call: 404.5
Target: 470
BUY
There has been a sharp deceleration in Laurus’ earnings trajectory over FY16-19E (11% compounded decline), led by increased competition in the Hep-C business, incremental overhead costs associated with the formulation business, raw material price hike due to stringent pollution norms in China and moderate growth in the ARV-API business. We expect earnings growth to revive over FY19-21 with contracts in place for formulations and addition of new molecules for the API business. We expect 69% earnings CAGR over FY19-21E to INR2.6b. We value Laurus at 18x 12M forward earnings (to factor in forward integration and strong growth in earnings) and arrive at a target price of INR470. We resume a Buy rating on the stock.
... Read more
30-Mar-19
Price @ Call: 407.96
Target: 535
BUY
Overall, we estimate 12/42/88% rev/EBITDA/earnings CAGR over FY19-21E. The stock is currently trading at attractive valuations of 22.6/13.5x FY20/21E EPS. We maintain BUY with a TP of Rs 535 (18x FY21E EPS). Refer our Jan-19 IC note for further details.
... Read more
6-Feb-19
Price @ Call: 351.2
Target: 480
BUY
10-Jan-19
Price @ Call: 373.91
Target: 480
BUY

LAURUSLABS Share Price Target - Broker Reports - 2018

6-Aug-18
Price @ Call: 469
Target: 552
BUY
11-May-18
Price @ Call: 485.8
Target: 586
BUY
5-Mar-18
Price @ Call: 533.7
Target: 613
BUY
30-Jan-18
Price @ Call: 515.54
Target: 613
BUY
16-Jan-18
Price @ Call: 538.09
Target: 651
BUY

LAURUSLABS Share Price Target - Broker Reports - 2017

18-Dec-17
Price @ Call: 521.5
Target: 633
BUY
1-Sep-17
Price @ Call: 526
Target: 570
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • LAURUSLABS Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3670
    Upside Target 2664.7
    Upside Target 1656.25
    Pivot650.95
    Downside Target 1642.5
    Downside Target 2637.2
    Downside Target 3628.75
  • LAURUSLABS Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3694.33
    Upside Target 2684.17
    Upside Target 1665.98
    Pivot655.82
    Downside Target 1637.63
    Downside Target 2627.47
    Downside Target 3609.28
  • LAURUSLABS Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3932.63
    Upside Target 2815.22
    Upside Target 1751.93
    Pivot634.52
    Downside Target 1571.23
    Downside Target 2453.82
    Downside Target 3390.53
  • LAURUSLABS Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3664.7
    Upside Target 2659.45
    Upside Target 1656.2
    Pivot650.95
    Downside Target 1645.7
    Downside Target 2642.45
    Downside Target 3637.2
  • LAURUSLABS Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3684.17
    Upside Target 2673.34
    Upside Target 1666.65
    Pivot655.82
    Downside Target 1644.99
    Downside Target 2638.3
    Downside Target 3627.47
  • LAURUSLABS Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3815.22
    Upside Target 2746.19
    Upside Target 1703.54
    Pivot634.52
    Downside Target 1565.49
    Downside Target 2522.84
    Downside Target 3453.82
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020